Personalis, Inc. Common Stock

Day range

$15.77 – $15.99

Open

$15.81

Prev close

$15.85

Volume

577.34K

Market cap

$1.69B

Shares out

104.72M

P/E

—

P/S

24.30

P/B

7.20

P/FCF

—

ROE

-45.6%

ROA

-34.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Merger agreementOct 6, 2026

  As previously disclosed, on July 20, 2026, Personalis, Inc. ... entered into an Agreement and Plan of Merger ... with Tempus AI, Inc. ... The Merger Agreement provides that ... Merger Sub I will merge with and into the Company ... and immediately thereafter, the Company will merge with and into Merger Sub II.

• Significant contract awardAug 20, 2026

  On August 20, 2026, Personalis, Inc. received a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA's Million Veteran Program (VA MVP). The new task order is effective on September 30, 2026 and has a value of up to $18.3 million, subject to the receipt of samples from the VA MVP and performance of services by Personalis.

• Acquisition consideration sharesJul 20, 2026

  At the Effective Time, each share of Company Common Stock issued and outstanding immediately prior to the Effective Time...will be automatically converted into the right to receive...a number of validly issued, fully paid and nonassessable shares of Parent Class A Common Stock equal to the Exchange Ratio (the 'Stock Consideration'); provided, however, that Parent may elect...to pay cash for up to 50% of the aggregate number of outstanding shares of Company Common Stock...each holder will receive: (a) an amount in cash equal to the Per Share Cash Consideration of $16.25 per share.

• Merger agreementJul 20, 2026

  the Company and Tempus announced that they entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Company, Tempus, Aviary Development, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Tempus ("Merger Sub I"), and Toucan Development, LLC, a Nevada limited liability company and a direct, wholly-owned subsidiary of Tempus ("Merger Sub II"), pursuant to which, subject to the terms and conditions of the Merger Agreement, (i) Merger Sub I will merge with and into the Company (the "First Merger"), with the Company surviving the First Merger as a direct, wholly-owned subsidiary of Tempus, and (ii) immediately following the First Merger, the Company will merge with and into Merger Sub II (the "Second Merger"), with Merger Sub II surviving the Second Merger as a direct, wholly-owned subsidiary of Tempus.

• Regulatory decisionMay 20, 2026

  On May 19, 2026, the Centers for Medicare & Medicaid Services Molecular Diagnostics Program expanded Medicare coverage for Personalis, Inc.'s ultrasensitive NeXT Personal® test to include monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Cancer (TNBC) or HER2-positive (HER2+) breast cancer.

Days to cover

4.3

Short interest

8.43M

Avg volume

1.95M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
  negativeGlobeNewswire Inc.· Sep 23, 2026
• BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
  negativeGlobeNewswire Inc.· Sep 3, 2026
• Why Tempus AI Skyrocketed This Week
  positiveThe Motley Fool· Aug 23, 2026
• PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI
  negativeGlobeNewswire Inc.· Aug 4, 2026
• PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus
  negativeGlobeNewswire Inc.· Aug 3, 2026